Accord Rolls Out Zercepac Trastuzumab Biosimilar In UK
Rival To Herceptin Was Developed By China’s Shanghai Henlius Biotech
Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.
You may also be interested in...
Shanghai Henlius Biotech and Accord Healthcare have broadened their collaboration on trastuzumab, with the Chinese company licensing its Zercepac biosimilar to Accord in the US and Canada. Meanwhile, Accord has launched a Pelgraz pegfilgrastim pre-filled injector and patient app in the UK.
Shanghai Henlius Biotech has received the first Chinese approval for a trastuzumab biosimilar version of Herceptin.
Shanghai Henlius Biotech is to make history with the first China-developed monoclonal antibody biosimilar in Europe, the firm’s Zercepac (trastuzumab) biosimilar that has been licensed to Accord Healthcare.